| Literature DB >> 19325921 |
Sahar I Mostafa1, Constantina Papatriantafyllopoulou, Spyros P Perlepes, Nick Hadjiliadis.
Abstract
The new complexes [M(2)O(5)L(2)(H(2)O)(2)] .Entities:
Year: 2009 PMID: 19325921 PMCID: PMC2659754 DOI: 10.1155/2008/647873
Source DB: PubMed Journal: Bioinorg Chem Appl Impact factor: 7.778
Scheme 1Structural formulae of pyrimidine-2-thione (I), and some of its amino (II, III) and hydroxy (IV, V) derivatives shown in one of their tautomeric forms.
Scheme 24,6-diamino-5-hydroxy-2-mercaptopyrimidine (LH).
Diagnostic1H NMR (δ, ppm)a spectral data for LH and the representative complexes 1, 3, 4, and 6–8 in DMSO-d6.
| Compound | –N(1)H– | –N(4)H2/–N(6)H2 | –O(5)H |
|---|---|---|---|
| LH | 7.43 | 6.07, 6.18 | 9.13 |
|
| 7.57 | 6.18, 6.55 | — |
|
| 7.49 | 6.14, 6.47 | — |
|
| 7.44 | 6.20, 6.49 | — |
|
| b | 6.11, 6.47 | — |
|
| 7.47 | 6.17, 6.48 | — |
|
| 7.39 | 6.08, 6.46 | — |
aThe spectra were run 10–15 min after dissolution.
bObscured by the signals of the aromatic protons.
Diagnostic ligand IR bands (cm−1) for LH and complexes 1–10.
| Compound |
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|
| LH | 3390 | 3185 | 2970 | 1652 | 1652 | 1455 | 1177 |
|
| 3377, 3330 | 3180, 3156 | 3005 | 1631 | 1553 | 1460 | 1155 |
|
| 3388, 3356 | 3188, 3160 | 3000 | 1633 | 1556 | 1465 | 1170 |
|
| 3399, 3343 | 3180, 3079 | 3010 | 1632 | 1558 | 1464 | 1157 |
|
| 3400, 3320 | 3160, 3105 | 3005 | 1642 | 1560 | 1460 | 1170 |
|
| 3387, 3320 | 3166, 3110 | 3010 | 1635 | 1556 | 1455 | 1177 |
|
| 3380, 3357 | 3170, 3095 | 3015 | 1641 | 1552b | 1443b | 1176 |
|
| 3395, 3357 | 3164, 3098 | 3010 | 1646 | 1550 | 1446 | 1170 |
|
| 3397, 3360 | 3165, 3100 | 3015 | 1640 | 1553 | 1450 | 1176 |
|
| 3400, 3355 | 3155, 3105 | 3012 | 1639 | 1555b | 1460b | 1170 |
|
| 3405, 3324 | 3180, 3100 | 3010 | 1641 | 1558 | 1462 | 1164 |
aOverlapping with the v(OH)water band in the spectra of 1–8.
bOverlapping with phenyl stretching vibrations of the coordinated PPh3 ligands.
Diameters (mm) of growth inhibitions zones for the antibacterial activity of LH and complexes 1, 4, 7, and 8.
| Compound |
|
| ||||||
|---|---|---|---|---|---|---|---|---|
| 10 | 20 | 50 | 100 | 10 | 20 | 50 | 100 | |
| LH | 5 | 11 | 28 | 58 | 4 | 10 | 30 | 55 |
|
| 13 | 22 | 47 | 99 | 10 | 17 | 41 | 83 |
|
| 10 | 17 | 42 | 86 | 9 | 14 | 39 | 77 |
|
| 8 | 13 | 29 | 49 | 7 | 13 | 30 | 44 |
|
| 10 | 19 | 43 | 80 | 7 | 13 | 32 | 61 |
amg/cm3 represents the concentration of the reagent in the gel.
Diameters (mm) of growth inhibition zones for the antifungal activity of LH and complexes 1, 4, 7, and 8.
| Compound |
|
| ||||||
|---|---|---|---|---|---|---|---|---|
| 10 | 20 | 50 | 100 | 10 | 20 | 50 | 100 | |
| LH | 5 | 12 | 23 | 44 | 6 | 9 | 34 | 55 |
|
| 15 | 21 | 43 | 91 | 13 | 19 | 44 | 89 |
|
| 10 | 17 | 40 | 79 | 9 | 16 | 38 | 68 |
|
| 0 | 0 | 0 | 0 | 6 | 11 | 21 | 37 |
|
| 6 | 15 | 31 | 63 | 7 | 16 | 33 | 68 |
| Nystatinb | 17 | 19 | 36 | 65 | 20 | 26 | 42 | 79 |
amg/cm3 represents the concentration of the reagent in the gel.
bA currently prescribed antifungal drug.
Scheme 3The proposed coordination mode of the anionic ligand L− in complexes 1–10; M=metal ion.
Figure 1Schematic structures proposed for the neutral complexes 1–5, 7, 10 and for the cations of complexes 6, 8, 9. Lattice H2O molecules and counterions have been omitted for clarity. However, and represent the ligands L− and phen, respectively. The N and O donor atoms of L− are the amino nitrogen of the position 6 (most probably) and the deprotonated oxygen of the position 5 of the pyrimidine ring; M=Mo, W; M′ = Rh, Ir.